No Data
Apogee Therapeutics Advances Phase 1 Clinical Trial for APG333 in Asthma and COPD With Interim Data Expected in 2H 2025
Express News | Apogee Therapeutics Inc - Interim Data From Phase 1 Trial Expected in 2H 2025
Express News | Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of Apg333, Its Novel Half-Life Extended Tslp Antibody for the Treatment of Respiratory and Broader I&I Conditions
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, Its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions
Insider Sale: Chief Medical Officer of $APGE (APGE) Sells 6,665 Shares
TD Cowen Maintains Apogee Therapeutics(APGE.US) With Buy Rating